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Abstract
Fanconi anemia (FA/BRCA) signaling network controls multiple genome-housekeeping 
checkpoints, from interphase DNA repair to mitosis. The in vivo role of abnormal cell division in 
FA remains unknown. Here, we quantified the origins of genomic instability in FA patients and 
mice in vivo and ex vivo. We found that both mitotic errors and interphase DNA damage 
significantly contribute to genomic instability during FA-deficient hematopoiesis and in non-
hematopoietic human and murine FA primary cells. Super-resolution microscopy coupled with 
functional assays revealed that FANCA shuttles to the pericentriolar material (PCM) to regulate 
spindle assembly at mitotic entry. Loss of FA signaling rendered cells hypersensitive to spindle 
chemotherapeutics and allowed escape from the chemotherapy-induced spindle assembly 
checkpoint. In support of these findings, direct comparison of DNA cross-linking and antimitotic 
chemotherapeutics in primary FANCA−/− cells revealed genomic instability originating through 
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divergent cell cycle checkpoint aberrations. Our data indicate that the FA/BRCA signaling 
functions as an in vivo gatekeeper of genomic integrity throughout interphase and mitosis, which 
may have implications for future targeted therapies in FA and FA-deficient cancers.
INTRODUCTION
Fanconi anemia (FA/BRCA) pathway is an intricate plexus of at least 17 proteins that 
maintain genomic stability, control growth and development, and prevent cancer. Bi-allelic 
germline disruption of any FA gene causes Fanconi anemia (FA), a genetic disorder 
characterized by developmental abnormalities, bone marrow failure (BMF), myelodysplasia 
and high risk of cancer, particularly acute myeloid leukemia (AML)1–5. Heterozygous 
inborn mutations in the BRCA branch of FA network increase risk of breast and ovarian 
cancers as well as other tumors5–9, and somatic mutations of FA/BRCA genes occur in 
malignancies in non-Fanconi patients10–13. Thus, disruption of FA/BRCA signaling 
promotes malignancies in the inherited genetic syndromes and in the general population.
The FA/BRCA pathway prevents cancer by protecting genome integrity. In interphase, DNA 
damage response (DDR) initiates the assembly of the multi-protein FA complex at damage 
sites to arrest the cell cycle as the cascade of effectors repairs the lesions1,5. These 
compartmentalized bursts of FA activity handle multiple genotoxic insults, from endogenous 
aldehydes14,15 to replication errors and mutagen exposure. Thus, the FA/BRCA network 
provides a crucial line of defense against interphase mutagenesis1,5.
Less is known about the role of the FA/BRCA pathway during mitosis, but FA signaling has 
been recently implicated in the maintenance of normal centrosome count16–19, spindle 
assembly checkpoint (SAC)17,20, repair of anaphase bridges21,22 and execution of 
cytokinesis23–25. Since chromosomal instability due to mitotic errors is a hallmark of 
cancer26,27 and a therapeutic target28, these findings may have translational relevance. 
However, it is unknown whether these ex vivo observations are applicable to in vivo 
hematopoiesis.
Here, we present quantitative evidence that loss of FA signaling disrupts mitosis during in 
vivo hematopoiesis in humans and mice, and that both aberrant interphase and mitotic failure 
contribute to genomic instability due to FA deficiency. Super-resolution microscopy 
revealed that FANCA shuttles to the pericentriolar material at mitotic entry to regulate 
centrosome-associated spindle nucleation. We found that primary FANCA−/− cells escape 
chemotherapy-induced SAC to replicate despite genomic instability. Our cell-survival 
assays showed that FA-deficient cells are hypersensitive to taxol (an antimitotic 
chemotherapeutic). Sublethal taxol doses exacerbated genomic instability in FA−/− cells 
through mitotic errors while low-dose MMC activated the G2/M checkpoint and DNA 
breakage. Therefore, distinct classes of chemotherapeutics inflict unique damage patters in 
FA−/− cells, which may have implications for future strategies against FA-deficient cancers. 
Together, our findings provide insights into complex mechanisms of genomic instability in 
FA.
Abdul-Sater et al. Page 2
Exp Hematol. Author manuscript; available in PMC 2016 December 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
METHODS
Cell culture
The primary patient fibroblast cells, FANCA−/− (MNHN, RA885), and FANCC−/− (WD-
C1, homozygous for FANCCc.377_378delGA), were received from Dr. Helmut Hanenberg 
(IU). MNHN cells harbor two FANCA mutations: c.3163C>T, and c.4124-4125delCA. Both 
FANCA-deficient lines have been published17. Most experiments were done using the 
MNHN cells unless otherwise noted. Fibroblasts and MEFs were cultured in DMEM 
containing 10% fetal bovine serum (FBS), 1% penicillin-streptomycin (pen-strep), and 1% 
sodium pyruvate in 37°C-5%CO2-5%O2 incubators to minimize oxidative damage. Primary 
human CD34+ cells (IU Simon Cancer Center Angio BioCore) were incubated at 
37°C-5%CO2-5%O2 in IMDM with 20% FBS, 1% pen-strep, 100 ng/ml SCF, 100ng/ml 
TPO, and 100ng/ml FLT3.
Mice
All animal experiments were approved by the Institutional Animal Care and Use Committee 
(IACUC) at IU School of Medicine. Fancc−/− mice29 were a gift from Dr. D. Wade Clapp 
(IU).
RBC micronucleation assays
50 µls of blood were collected from the murine lateral tail vein into EDTA-coated collection 
tubes containing methanol (2 mls, pre-chilled at −80°C for >1hr) and stored in −80°C. Next, 
10ml PBS was added, cells were pelleted at 600×g (5 minutes, 4°C). The supernatant was 
aspirated and RBCs were resuspended in residual methanol/PBS. 20 µl aliquots were 
transferred to flow tubes and incubated in the dark with 90 µls of FITC-conjugated anti-
mouse CD71 (Biolegend)+1 mg/ml RNAse A (Roche) first for 30 minutes at room 
temperature (RT) and then 30 minutes on ice. Propidium iodide staining (Invitrogen) at 1.25 
µg/ml was followed by flow cytometry on a FacsCalibur machine (Becton-Dickinson). At 
least 500,000 events/sample were acquired. Hemavet 950FS (Drew Scientific) was used for 
blood counts.
Deconvolution and super-resolution microscopy
Cells grown on ultrafine glass coverslips (Fisher) were fixed with 4% 
paraformaldehyde/PBS for 15 minutes (RT), PBS-washed, permeabilized with 0.1% Triton 
X-100/PBS for 10 minutes, PBS-washed, blocked in 5% bovine serum albumin (BSA)/PBS 
or ImageIT SignalEnhancer (Life Technologies) for 1 hour, and then incubated in primary 
antibody in 1% BSA/PBS overnight (4°C) or 2 hours (RT). Antibodies are listed in 
Supplemental Information. Next, cells were PBS-washed and incubated with secondary 
antibodies (1:2000, 1% BSA/PBS) for 30 minutes (RT), PBS-washed, counterstained with 
Hoechst-33342 (Life Technologies) in PBS (1:10,000) for 10 minutes, washed and mounted 
in SlowFade Antifade (Life Technologies).
For deconvolution microscopy, image stacks (z-section distance: 0.2µm) were acquired on a 
Deltavision personalDx microscope (Applied Precision) with a CCD camera using 20×, 60× 
or 100× lenses, and deconvolved using Softworx. Super-resolution structured illumination 
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microscopy (SR-SIM) images were acquired on a Zeiss ELYRA PS.1 system with a CCD 
camera and 60×/100× lenses, and processed via SIM/channel-alignment algorithms 
(Zen-2011; Zeiss). Line-intensity profiles were quantified using Imaris (Bitplane). Z-
sections shown on figures were exported using Imaris.
Images of FA patient marrow aspirates, marrow aspirates of patients diagnosed with 
immune-mediated aplastic anemia with negative chromosome breakage test results, marrow 
cytospins and peripheral smears were obtained on Zeiss Axiolab microscope with 
Axiocam-105 color camera.
Cytokinesis-block micronucleus assays
Fibroblasts and MEFs grown on coverslips were treated with cytochalasin B (2µg/ml) for 24 
hours followed by processing/imaging as above; anti-CENPA immunofluorescence 
visualized endogenous kinetochores. For drug treatments, cells were exposed to 1nM taxol 
or MMC for 9 days before cytochalasin B for 24 hrs. A micronucleus was defined based on 
the following criteria: (1) the diameter of the micronucleus must be less than ½ of the main 
nucleus and (2) nuclear boundary must be identified between the micronucleus and the 
nucleus. The presence of kinetochores was determined based on visualization of CENPA+ 
foci within the stack of z-sections spanning the entire micronucleus.
For CD34+ experiments, primary human CD34+ cells transduced with GFP-tagged 
lentiviral shRNA constructs were cultured for 5 days, sorted on a SORPAria FACS system, 
attached to coverslips via cytospin (450rpm, 7 minutes), and analyzed in 
immunofluorescence assays as above.
Mitotic spindle assembly assay
Culture plates with live fibroblasts on coverslips were removed from the 37°C incubator to 
replace growth medium with pre-chilled medium and kept in 4°C (1 hour). Next, the cold 
medium was replaced with pre-warmed medium (37°C), cells were returned to 37°C (15 
seconds), and immediately fixed (4% paraformaldehyde/PBS). Upon staining with anti-
pericentrin and anti-α-tubulin, cells were imaged via deconvolution microscopy. Imaris 
(Bitplane) was used to measure length of microtubules in z-sections and count centrosome-
associated microtubules within stacks.
Statistics
Statistical analyses were performed using GraphPad Prism 6; p<0.05 was considered 
significant.
Study approval
Patients had been enrolled on the IRB-approved protocol at IU School of Medicine 
(IRB#1108006474). All animal experiments were approved by the Institutional Animal Care 
and Use Committee (IACUC) at IU School of Medicine.
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RESULTS
In vivo error-prone mitosis during FA−/− hematopoiesis
Mitotic failure was reported in FA cells ex vivo, and cytokinesis failure was documented in 
FA marrows17,23. However, the in vivo evidence of abnormal early mitosis in hematopoietic 
cells of FA patients has been missing. To examine whether loss of FANCA (the gene most 
commonly disrupted in FA5) predisposes hematopoietic cells to erratic divisions in vivo, we 
quantified mitotic errors in marrow aspirates of two FANCA−/− patients with pancytopenia 
but no MDS/AML. Consistent with the role of FANCA in cell division, we observed 
increased frequency of abnormal mitotic figures in FANCA−/− marrows compared to 
marrow aspirates of patients diagnosed with immune-mediated aplastic anemia after 
excluding FA by negative chromosome breakage tests (Figure 1A, p=0.01). Lack of 
chromosome congression leading to lagging chromosomes in anaphase and micronucleation 
at mitotic exit reflects weakened SAC or merotelic attachment due to centrosome 
malfunction17. The DNA bridges in late mitosis may reflect impaired resolution of ultrafine 
anaphase bridges21. Interphase nuclear morphology in the erythroid lineage provided further 
evidence of in vivo mitotic abnormalities (Figure 1B–C). Erythroblast micronucleation 
(Figure 1B) suggests failure to segregate chromosomes into the daughter nuclei. Presence of 
bizarre erythroblasts with multilobed nuclei (Figure 1B) is consistent with impaired 
chromosome segregation due to erroneous SAC followed by cytokinesis failure17,23. 
Binucleated erythroblasts (Figure 1B) reflect lack of cytokinesis after normal chromosome 
division23. These results provide quantitative in vivo evidence that abnormal mitoses occur 
with increased frequency in the hematopoietic cells of FANCA−/− patients before 
development of MDS/AML.
We next validated these findings in a different in vivo experimental system. We examined 
hematopoietic chromosomal instability in living Fancc−/− mice using an in vivo erythrocyte 
micronucleation assay30,31. This assay is based on the notion that genomically unstable 
orthochromatic erythroblasts fail to extrude micronuclei, producing micronucleated red 
blood cells (RBCs). Indeed, we observed micronucleated RBCs in FA patients’ marrows 
(Figure 1C). These micronucleated RBCs are identified via flow cytometry as DNA-
containing CD71− RBCs (Figure 1D). 3-month old Fancc−/− mice released almost three-
fold more micronucleated mature RBCs into the peripheral blood compared to age-matched 
controls (Figure 1D, p<0.0001). Importantly, blood counts demonstrated no differences 
between the age-matched wt and Fancc−/− mice (Supplemental Table 1). Thus, disruption 
of two different FA core genes (FANCA and Fancc) leads to chromosomal instability during 
in vivo hematopoiesis in humans and mice before the onset of clinically significant BMF, 
myelodysplasia or leukemia.
A combination of interphase and mitotic errors drives genomic instability in FA
Since BMF and hematopoietic malignancies are consistent clinical hallmarks of FA1,5, we 
quantified the contribution of interphase and mitotic abnormalities to genomic instability in 
FANCA-deficient hematopoietic cells. A modified micronucleus assay (Figure 2A)32 
allowed to determine the origin of multinucleation in primary human CD34+ hematopoietic 
cells transduced with an shRNA against FANCA17 compared to control CD34+ cells. We 
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validated the FANCA shRNA in human CD34+ cells (Figure 2B–C). Upon FANCA 
knockdown, CD34+ cells were immunostained for endogenous CENPA (a kinetochore 
marker33) and imaged by deconvolution microscopy to classify cells based on the presence 
of CENPA+ foci. As described32, additional kinetochore-positive nuclei arise through 
whole-chromosome missegregation in mitosis, and supernumerary kinetochore-negative 
nuclei result from DNA fragmentation (Figure 2A). FANCA-knockdown CD34+ cells 
developed higher multinucleation due to both chromosome breakage (p=0.0083) and faulty 
chromosome segregation (p=0.0001) compared to control CD34+ cells (Figure 2D–E). We 
concluded that silencing FANCA impairs both interphase and mitotic genome maintenance 
in human hematopoietic cells.
To validate this finding in primary FA-deficient patient cells and eliminate the possibility of 
non-specific shRNA-induced phenotype34, we pursued cytokinesis-block cytome assays32. 
Dividing cells are treated with cytochalasin B (a cytokinesis inhibitor) prior to CENPA 
immunofluorescence. Inhibition of cytokinesis generates binucleated cells upon error-free 
chromosome partition, and the presence of micronuclei indicates abnormal chromosome 
segregation during the last mitosis. Again, CENPA-positivity distinguishes mitotic-failure 
micronuclei from DNA-breakage micronuclei (Figure 3A)35.
FANCA−/− fibroblasts had increased frequency of both chromosome missegregation 
(p=0.0391) and chromosome breakage (p=0.0218) compared to isogenic gene-corrected 
cells (Figure 3B–C). Similarly, Fancc−/− MEFs demonstrated an increased incidence of 
micronucleation resulting from both chromosome breakage (p=0.0004) and chromosome 
missegregation (p=0.078) compared to wt MEFs (Figure 3D–E). Thus, disruption of FA 
signaling impairs interphase and mitotic fidelity not only during hematopoiesis (Figure 2), 
but also in fibroblasts and MEFs (Figure 3). These findings suggest that multiple FA/BRCA 
proteins may play evolutionarily conserved roles in mitotic genome housekeeping.
FANCA regulates centrosome-mediated spindle microtubule assembly in early mitosis
We and others have reported defects in centrosome amplification in cells lacking the FA/
BRCA pathway16–19, but the impact of FA signaling on mitotic centrosome function per se 
has not been studied. At mitotic entry, maturing centrosomes nucleate microtubules to build 
the mitotic spindle36. These microtubules undergo controlled rearrangements to properly 
capture kinetochores before anaphase begins37. Since FANCA localizes to the mitotic 
apparatus16,17 and FA signaling is implicated in the SAC17, we wondered whether FANCA 
regulates the dynamic equilibrium of spindle microtubule assembly in early mitosis. We 
quantified the ability of primary patient-derived FANCA−/− and FANCA+ fibroblasts to 
establish spindles in modified spindle assembly assays (Figure 4A)38. Live cells were first 
placed at 4°C to destabilize microtubules (Figure 4B) and then given pre-warmed growth 
medium to stimulate spindle regrowth, fixed and analyzed via quantitative deconvolution 
microscopy. Prometaphase FANCA−/− centrosomes demonstrated impaired spindle-
nucleating ability evidenced by decreased number of microtubules emanating from each 
centrosome (Figure 4C–D, p≤0.0001). The spindle microtubules nucleated by FANCA−/− 
centrosomes were shorter (Figure 4E, p≤0.0001) than microtubules assembled in gene-
corrected cells. Importantly, FANCA−/− cells containing supernumerary centrosomes16,17 
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were excluded from the analysis. Therefore, FANCA is essential not only for the 
maintenance of centrosome number, but also for efficient mitotic spindle assembly. Super-
resolution structured illumination microscopy (SR-SIM) revealed endogenous FANCA on 
mitotic centrosomes in close proximity of spindle microtubules (Figure 4F–G), consistent 
with the role of FANCA in spindle dynamics.
FANCA shuttles to the pericentriolar material during mitotic centrosome maturation
Multiple FA proteins, including FANCA (Figure 4F–G), localize to centrosomes and mitotic 
spindles16–18. However, it is unknown whether FANCA association with centrosomes 
changes between interphase and mitosis, as expected of a bona fide regulator of mitotic 
centrosome/spindle function39,40.
Centrosome maturation prepares centrosomes for mitosis through reorganization of the 
pericentriolar material (PCM). A phosphosignaling circuit of cyclin-dependent kinases 
(CDKs), polo-like kinase 1 (PLK1) and Aurora A41 recruits pericentrin39 and γ-tubulin40 to 
the PCM at mitotic entry to increase the spindle-nucleating centrosome activity42. Since 
FANCA regulates spindle assembly (Figure 4B–E), we wondered whether FANCA is 
recruited to the PCM of maturing centrosomes similar to these other centrosome-spindle 
regulators. To examine FANCA sub-centrosomal localization, we employed deconvolution 
and super-resolution microscopy, which allows visualization of centrosomes beyond the 
diffraction limit imposed by conventional microscopes43,44. At mitotic entry, FANCA 
shuttled from centrioles towards the PCM and co-localized with pericentrin, γ-tubulin and 
the minus end of spindle microtubules until the mitotic exit (Figure 5A–B, Supplemental 
Figures 4–7). In interphase, FANCA returned to the mother centriole (Supplemental Figure 
8). These observations were confirmed with multiple primary antibodies and imaging of 
FANCA−/− patient cells stably expressing GFP-FANCA.
To thoroughly analyze FANCA distribution within the PCM, we analyzed individual 84-nm-
thin super-resolution sections of mitotic centrosomes. At the mid-centrosome level, we 
observed well-organized FANCA fibers extending through and beyond the pericentrin-
decorated PCM network from centrioles towards microtubule nucleation sites (Figure 5B–
C). This dynamic relocalization of FANCA to the PCM during mitosis supports the newly 
discovered role of FANCA in spindle microtubule nucleation (Figure 4).
Loss of FANCA allows escape from SAC arrest and apoptosis
The FA/BRCA pathway repairs interphase DNA damage45,46 and participates in the spindle 
assembly checkpoint (SAC)17. To examine the fate of FANCA-deficient cells upon SAC 
activation, we employed time-lapse imaging of primary FANCA−/− and gene-corrected 
cells treated with taxol, a microtubule-stabilizing chemotherapeutic (Figure 6A). As 
described in other cells47,48, FANCA-corrected, taxol-exposed cells entered prolonged 
prometaphase arrest followed by cell death without exiting mitosis. FANCA−/− cells were 
more likely to escape taxol-induced SAC arrest and generate multinucleated interphase-like 
cells (p=0.0215; Figure 6B–E). These findings validate the role of FANCA in the SAC and 
show that loss of FANCA facilitates the escape of chromosomally unstable cells from mitotic 
death caused by unsatisfied SAC47.
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FANCA−/− cells are hypersensitive to taxol
A significant fraction of multinucleated cells that escape taxol-induced arrest49 or form upon 
failed mitosis50,51 is physiologically eliminated to prevent genomic instability26,52. 
Complete SAC disruption causes chromosomal instability incompatible with cell survival53. 
Thus, we hypothesized that loss of FANCA may render cells hypersensitive to taxol.
Since previous studies evaluating response of FA−/− cells to anti-mitotic chemotherapeutics 
generated conflicting data16,54, we performed rigorous dose-response experiments to 
thoroughly examine this concept. We found that two separate FANCA−/− primary patient 
cell lines harboring different FANCA mutations are hypersensitive to taxol; stable FANCA 
expression rescued taxol hypersensitivity in both lines in two independent cell viability 
assays (Figure 6F–H, Supplemental Figures 7–8). Likewise, FANCC−/− primary fibroblasts 
displayed taxol hypersensitivity compared to FANCC-corrected cells (Supplemental Figure 
8C). As expected1,5, FANCA−/− and FANCC−/− cells showed decreased survival upon 
exposure to the crosslinking agent mitomycin C (MMC) (Figure 6F–H; Supplemental 
Figures 2,9). These findings, together with previously published work16, indicate that loss of 
FANCA or FANCC is synthetically lethal with exposure to anti-mitotic chemotherapeutics.
Chemotherapy-exposed FANCA−/− cells develop distinct patterns of genomic instability 
due to separate interphase and mitotic checkpoint abnormalities
Having established the hypersensitivity of FA−/− cells to interphase DNA crosslinkers and 
anti-mitotic agents, we wanted to understand how loss of FANCA confers hypersensitivity 
to these separate classes of chemotherapeutics. Thus, we examined cell cycle and patterns of 
genomic instability in primary FANCA−/− and gene-corrected cells at baseline 
(Supplemental Figure 10) and upon treatment with sublethal doses of MMC and taxol. We 
selected drug doses that decreased growth of FANCA−/− cells compared to isogenic 
FANCA+ cells without fully arresting FANCA−/− cells or inducing cell death evidenced by 
increased sub-G1 fraction on flow cytometry (Figure 7A and not shown).
Prolonged treatment with 1 nM MMC reduced growth of FANCA−/− cells due to persistent 
activation of the G2/M checkpoint (p=0.0376) reflected by decreased DNA replication 
(p<0.0001) and decreased G1 fraction (p=0.0029) (Figure 7A–D). This observation is 
consistent with the exaggerated MMC-induced G2/M arrest of FA cells due to the DDR 
failure45,46. In further support of this notion, exposure to low-dose MMC increased 
multinucleation due to DNA breakage (p=0.0223) but not chromosome missegregation 
(Figure 7E–G). Sublethal taxol exposure affected FANCA−/− cells differently. Prolonged 
treatment with low-dose taxol (but not MMC) significantly decreased the mitotic fraction of 
FANCA−/− cells compared to gene-corrected cells (Figure 7H–I, p<0.0001) consistent with 
impaired SAC (Figure 6). Furthermore, low-dose taxol increased multinucleation of FANCA
−/− patient cells (p=0.002) secondary to mitotic chromosome missegregation (p<0.0001) as 
well as chromosome breakage (p=0.0059) (Figure 7J–K). Interestingly, multinucleated cells 
continued to enter S-phase (Supplemental Figure 11)52,55.
In summary, these results (i) provide evidence that both impaired DDR and error-prone 
mitosis contribute to chromosomal instability in FANCA−/− cells in vivo and ex vivo, (ii) 
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offer insights into the role of FA pathway in the response to DNA-crosslinking agents and 
anti-mitotic chemotherapeutics, and (iii) open potential new inroads towards synthetic lethal 
chemotherapy against FA-deficient cancers.
DISCUSSION
Disrupted FA/BRCA signaling causes genomic instability and cancer. The FA/BRCA tumor 
suppressor network orchestrates interphase DDR and DNA replication1,5. Multiple lines of 
evidence implicated FA/BRCA signaling in centrosome maintenance and mitotic 
checkpoints16–19,21,23, but the in vivo importance of these findings is unknown. We found 
that both abnormal interphase and error-prone mitosis significantly contribute to the in vivo 
hematopoietic genomic instability in FA−/−humans and mice, suggesting a role for the FA/
BRCA network in genome surveillance throughout the cell cycle (Figure 7L).
FANCA−/− patients’ hematopoiesis is afflicted by mitotic errors. Lagging chromosomes 
due to an in vivo SAC impairment17 and persistent anaphase/telophase bridges21,22 occur 
with increased frequency in FANCA−/− patients (Figure 1). In agreement with the work 
from the D’Andrea group23, bi-nucleated hematopoietic cells (Figure 1) are signs of faulty 
cytokinesis. Increased chromosome missegregation during erythropoiesis in Fancc−/− mice 
(Figure 1D–E) indicates that other FA/BRCA proteins are essential for in vivo high-fidelity 
chromosome partition in hematopoietic cells in an evolutionary conserved manner. The 
onset of FA-associated mitotic abnormalities precedes the MDS/AML (Figure 1; 
Supplemental Table 1), suggesting that impaired mitosis may contribute to carcinogenesis in 
FA. Indeed, FISH analysis detected chromosomally unstable clones in 15% of FA patients 
with morphologically normal marrows56, and gross chromosomal instability is a hallmark of 
MDS/AML in FA57. More research is needed to quantify the impact of haphazard mitosis on 
FA-associated myelodysplasia and cancer.
The irregular mitosis during FA−/− hematopoiesis is a consistent but relatively rare event 
(Figures 1–2). Further, while multinucleated cells with centrosome clusters are easily seen in 
FA-deficient cancer cells17, multinucleation in FA−/− primary cells is more subtle (Figures 
2–3)17, perhaps because cancers cannot eliminate mis-dividing cells through backup 
checkpoints. Indeed, centrosome abnormalities induce TP53-dependent cell cycle arrest51 
and apoptosis50, and activation of TP53 contributes to BMF in FA58. TP53 inactivation 
boosts hematopoiesis but promotes MDS/AML in FA59, and AML with bizarre karyotype 
instability occurred in an FA patient with somatic loss of heterozygosity of the TP53-
harboring region of chromosome 1760. Thus, aneuploidy and centrosome disruption upon 
inactivation of the FA/BRCA signaling may trigger TP53-dependent checkpoints to limit the 
risk of leukemia at the cost of BMF.
The role of FANCA in mitosis is not clearly defined. Impaired FA signaling promotes 
accumulation of centrosomes due to DDR-induced centrosome over-replication18,19 and 
deregulated mitosis17,23. Supernumerary centrosomes promote chromosomal instability 
through multiple mechanisms26,61. We found that FANCA regulates centrosome-associated 
spindle assembly (Figure 4), and FANCA shuttles from centrioles to the PCM spindle 
attachment sites at mitotic entry (Figures 4–5). Dissecting FANCA-dependent mitotic 
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centrosome-microtubule-kinetochore interactions in more detail will help understand how 
FANCA regulates the SAC17. We hypothesize that functional and numerical centrosome 
abnormalities in FA-deficient cells may further promote chromosomal instability by 
promoting merotelic kinetochore attachment to spindle microtubules; this mechanism of 
genomic instability has been elucidated in non-FA cells acquiring supernumerary 
centrosomes61,62. Interestingly, FANCA is phosphorylated by the NIMA-related kinase 2 
(NEK2)16 and AKT kinase63; FANCJ and FANCD1 may regulate polo-like kinase 1 
(PLK1)18,19, which is essential for spindle function64; and FANCC binds the key mitotic 
cyclin-dependent kinase 1 (CDK1)65, which co-immunoprecipitates with the FA core 
complex66. Moreover, loss of FANCA is synthetic lethal with PLK1 knockdown67 and CDK 
inhibitors disrupt IR-induced formation of FANCD2 foci68. Future work will examine these 
pathway connections to evaluate their translational relevance in cancer and FA.
We found that loss of FA signaling is synthetically lethal with taxol exposure, highlighting 
the role of FA-dependent SAC in cell survival. Kim et al observed hypersensitivity of 
FANCA-knockdown cells to nocodazole16. Taxol and nocodazole are mechanistically 
different69: nocodazole disrupts spindle-kinetochore attachment, while taxol renders the 
attached microtubules unable to stretch the kinetochores. Since the FA pathway is essential 
for taxol- and nocodazole-induced SAC17, FANCA may regulate SAC by intra-kinetochore 
tension.
Of note, others have found that FANCG/FANCC-deficient pancreatic cancer cells exposed to 
taxol accumulate DNA at similar rate as gene-corrected cells in in vitro fluorescence 
assays54, and concluded that FA−/− cells are not hypersensitive to antimitotics. However, 
FA−/− cells multinucleate (Figure 6)16,17 and replicate (Supplemental Figure 11) upon 
exposure to antimitotics, suggesting why cell growth assays quantify taxol response with 
better specificity than total DNA measurements. Interestingly, low-dose taxol promotes 
chromosome missegregation and DNA breaks in FANCA−/− cells. Consistent with this 
notion, the Pellman group demonstrated that micronuclei produced by mitotic errors 
undergo excessive mutagenesis52 with secondary chromosome breakage55 due to erratic 
replication. The micronucleus-associated chromosome breakage may be further exacerbated 
by failed DDR in FANCA−/− micronuclei.
Micronucleation has been noted in FA for decades70,71, but it was unclear whether it reflects 
interphase abnormalities or erratic mitoses. We addressed this question with quantitative 
high-resolution-imaging-based micronucleation assays validated in previous studies32. 
Given the key role of FA signaling in interphase1,5, we have made effort to confirm that 
kinetochore-containing micronuclei are not produced simply by impaired DDR. Importantly, 
DNA-crosslinking agent (MMC) produced “DNA breakage” micronuclei but not 
“chromosome missegregation” micronuclei (Figure 7F–G), confirming the assay’s 
specificity and sensitivity in distinguishing interphase from mitotic errors. Thus, we 
concluded that genomic instability results from DNA breakage and chromosome 
missegregation in multiple FA−/− hematopoietic and non-hematopoietic cell types (Figures 
2–3). Based on these and other findings17, we propose that FANCA deficiency causes 
genomic instability through a dual mechanism of impaired interphase DDR/replication and 
defective mitosis72 (Figure 7L). This model explains the FA-associated patterns of genetic 
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instability and hypersensitivity to both DNA-crosslinkers and antimitotics. Interphase errors 
exacerbate mitotic abnormalities and mitotic failure promotes interphase mutagenesis. 
Chromatid remnants generated through impaired DDR or replication are randomly 
segregated in mitosis. Defective midbody constriction25 and cytokinesis23 may shatter 
lagging chromosomes resulting from impaired SAC17,73 and break unresolved anaphase 
bridges21,22. After mitotic exit, cells may attempt to repair splintered DNA through 
chromothripsis, the mutagenic process of randomly reconnecting chromosome fragments via 
non-homologous end joining (NHEJ)74–76. Since FA−/− cells favor error-prone NHEJ over 
homologous recombination77, chromothripsis may have a particularly detrimental impact on 
genomic stability upon loss of the FA/BRCA network.
Our observations unveil the translational importance of mitotic defects caused by loss of FA/
BRCA signaling. Somatic disruption of FA/BRCA genes occurs in malignancies in non-FA 
patients, including leukemia12,13,78,79, cervical10, ovarian11,80,81, breast82, bladder83 and 
lung cancers84. Our analysis of the COSMIC85 database revealed multiple cancer-associated 
FANCA and FANCC-inactivating mutations in non-FA patients (Supplemental Figure 13). 
Since FA−/− cells are hypersensitive to antimitotics, future preclinical studies will determine 
whether targeting mitosis can be employed in FA-deficient cancers. This strategy may 
complement other evidence-driven precision medicine efforts against FA−/− cancers, such 
as targeting PARP-dependent DNA repair pathways86–88, DNA damage kinases89 and 
selective use of crosslinkers11,68.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. In vivo chromosomal instability and abnormal mitoses during human FANCA−/− and 
murine Fancc−/− hematopoiesis
(A) Representative abnormal mitoses in FANCA−/− patient bone marrow aspirates. 
Quantification (upper right) represents data from 2 different FA patients and 2 non-FA 
patients (96 mitoses in non-FA and 73 mitoses in FA; Fisher’s exact test). Scale bars: 5 µm. 
(B) Examples of abnormal interphase nuclear morphology in FANCA−/− patients’ 
hematopoietic cells that have undergone aberrant mitoses compared to a normal non-FA 
interphase erythroblast. Scale bars: 5 µm (C) Micronucleation of FANCA−/− bone marrow 
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erythroblasts, reticulocytes and mature red blood cells (top) and Fancc−/− murine RBCs in 
peripheral blood (bottom). Scale bars: 5 µm (top); 2µm (bottom). (D) Increased frequency of 
CD71−, PI+ micronucleated mature RBCs in peripheral blood of 3-month-old Fancc−/− 
mice. (E) Quantification of micronucleated RBCs identified by flow cytometry is shown as 
fold change relative to wild-type levels. Bars indicate mean +/− SEM; >10 age-matched 
mice/genotype from multiple independent experiments were analyzed using a student’s t-
test. All specimens were imaged with Zeiss Axiolab system equipped with an Axiocam 105 
color camera.
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Figure 2. FANCA maintains genomic integrity during interphase and mitosis in primary human 
CD34+ cells
(A) Assay schematic. Kinetochore/centrosome immunofluorescence staining distinguishes 
multinucleation generated through whole-chromosome missegregation from multinucleation 
resulting from DNA breakage. (B) FANCA shRNA efficiently knocks down FANCA protein 
in primary human CD34+ cells. β-actin serves as loading control. (C) Functional validation 
of FANCA shRNA in primary human CD34+ cells. FANCA shRNA renders CD34+ cells 
hypersensitive to mitomycin C compared to CD34+ cells compared with control shRNA. 
Error bars represent mean +/− SEM and significance was determined using a two-way 
ANOVA with Sidak correction. (D) Representative images of multinucleation resulting from 
FANCA knockdown in human CD34+ cells. Regions of interests are marked in red or 
yellow and enlarged on the right. Green arrow points to a CENPA-positive centromere/
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kinetochore within the supernumerary nucleus. Scale bars: 2µm (left) and 1µm (right) (E) 
Quantification of multinucleation resulting from weakened SAC or chromosome breakage in 
control and FANCA-knockdown CD34+ cells. At least 500 cells per group were counted. 
Results were analyzed using a student’s t-test and represented as mean +/− SEM.
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Figure 3. Micronucleation upon loss of FA signaling results from a combination of interphase 
and mitotic errors
(A) Schematic of cytokinesis-block micronucleus test that discriminates the origin of 
aneuploidy based on the presence or absence of kinetochores within micronuclei. (B) 
Representative images of micronuclei in FANCA−/− primary patient fibroblasts. Scale bars: 
10µm (left) and 2µm (right) (C) Quantification of micronuclei resulting from whole-
chromosome missegregation versus chromosome breakage in primary FANCA−/− and 
FANCA+ fibroblasts. Error bars represent mean +/− SEM. (D) Representative images of 
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micronuclei in Fancc−/− MEFs. Scale bars: 10µm (left) and 2µm (right) (E) Quantification 
of micronucleation resulting from chromosome missegregation and chromosome breakage 
in wt and Fancc−/− MEFs. At least 260 cells were counted per condition and significance 
was determined by student’s t-test. Cells were imaged with deconvolution microscopy 
(Applied Precision personalDx) and deconvolved with Softworx imaging suite (10 
iterations, ratio: conservative).
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Figure 4. Loss of FANCA disrupts spindle microtubule assembly at prometaphase centrosomes
(A) Experiment design. Microtubules of living FANCA−/− and FANCA+ cells were 
destabilized by cold treatment (4°C for 1 hour). Cells were then returned to 37°C to initiate 
microtubule reassembly and fixed with 4% paraformaldehyde 15 seconds later. (B) Cold 
treatment fully destabilizes microtubules in FANCA+ and FANCA−/− prometaphase cells. 
(C) Representative images of mitotic spindle assembly in FANCA+ and FANCA−/− 
prometaphase cells stained with anti-α-tubulin (green) and anti-pericentrin (red) antibodies. 
Images were captured with 60× lens on the Deltavision deconvolution microscope. Scale 
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bars: 2µm (left and right) and 500nm (region of interest showed in the center). (D, E) 
Quantification of spindle microtubules per centrosome (D) and the microtubule length (µM) 
(E) in gene-corrected and FANCA−/− cells treated as described in (A). Data represents 2 
independent experiments (n=130 microtubules/experiment), and error bars represent SEM. 
(E) Representative mitotic HeLa cell stained with anti-FANCA (red) and anti-α-tubulin 
(green) antibodies, imaged on an ELYRA PS.1 super-resolution microscope using SIM 
technology. Insert shows enlarged centrosome-containing region of interest. White line 
shows the line of fluorescence intensity profile. Scale bar: 2µm. Cells were imaged with 
deconvolution microscopy (Applied Precision personalDx) and deconvolved with Softworx 
imaging suite (10 iterations, ratio: conservative). (F) Fluorescence intensity profiles of 
FANCA (red) and α-tubulin (green) signal.
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Figure 5. FANCA shuttles to the pericentriolar material during mitosis
(A) HeLa cells were immunostained with antibodies against endogenous FANCA (red) and 
centrin (green), imaged with deconvolution microscopy (Applied Precision personalDx) and 
deconvolved with Softworx imaging suite (10 iterations, ratio: conservative). Fluorescence 
intensity profiles demonstrate that FANCA colocalizes with centrin in interphase and 
migrates away from centrioles at metaphase. Scale bars: 1.5 µm (left) and 300 nm (right) (B) 
Representative super-resolution image of human fibroblast stably expressing GFP-FANCA 
and stained with antibody against the pericentriolar material marker (pericentrin). Inserted 
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3D rendering of the centrosome shows colocalization of GFP-FANCA and pericentrin. Scale 
bars: 2 µm. The yellow region of interest is magnified (C) to show FANCA fibers embedded 
within the PCM (centrosome cross-section) and extending towards the spindle (centrosome 
outer layer section). Fluorescence intensity profiles (right) of GFP-FANCA/pericentrin 
signal at PCM and spindle are shown on the right. Scale bar: 500 nm. SR-SIM images were 
acquired on Zeiss ELYRA PS.1 super-resolution microscopy system and exported using 
Imaris imaging suite.
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Figure 6. Loss of FANCA promotes escape from SAC and is synthetic lethal with low-dose taxol 
exposure
(A) Assay schematic. Prolonged activation of SAC triggers cell death to prevent genomic 
instability by eliminating cells that cannot satisfy the checkpoint. Escape from SAC 
followed by erratic chromosome segregation and mitotic exit generates multinucleated cells. 
(B) Representative time-lapse imaging snapshots of FANCA+ and FANCA−/− cells exposed 
to taxol. Note prolonged SAC arrest followed by cell death in gene-corrected cell and escape 
for SAC followed by cytokinesis failure and multinucleation in FANCA−/− cell. Scale bar: 
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15 µm. Time from mitotic entry is shown for each frame. Time-lapse phase-contrast frames 
of cells grown in DMSO supplemented with 10% FBS at 37°C, 5% CO2 were acquired 
every 2 minutes for at least 24 hours on a Nikon Biostation live-imaging system (C, D) 
Quantification of time-lapse imaging experiments. FANCA−/− cells are more likely to 
escape SAC and less likely to be eliminated through SAC-associated death compared to 
gene-corrected isogenic cells (p=0.0215). Data for 115 mitotic FANCA+ cells and 129 
mitotic FANCA−/− cells (three experimental replicates for each cell line) were analyzed 
with two-tailed t-test. See Supplemental Movies 1–2. (E) Prolonged prometaphase arrest in 
FANCA+ cells and multinucleation in FANCA−/− cells upon 24-hour exposure to taxol in 
an independent experiment. Images acquired on an Applied Precision personalDx 
deconvolution microscope. (F) Representative colony-forming (CFU) assay plates. Primary 
FANCA−/− fibroblasts and FANCA”+ fibroblasts (500 cells per 10 cm2 plate) were exposed 
to taxol for 11 days. Note decreased colony formation on FANCA−/− plates exposed to 1 
nM of taxol. (G) Quantification of the CFU assay shown in (F). FANCA−/− cells are more 
sensitive to 1 nM taxol than FANCA+ cells in the CFU assay. 1 nM MMC was used as 
positive control. (H) Direct cell counts confirm that stable expression of FANCA rescues 
both taxol and MMC hypersensitivity of FANCA−/− patient cells. Two-way ANOVA with 
Sidak correction was used for data comparison. Data show pooled results of three separate 
experiments, expressed as the mean ± SEM in triplicates.
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Figure 7. FANCA−/− cells exposed to genotoxic stressors develop genomic instability through a 
combination of interphase and mitotic checkpoint abnormalities
(A) Prolonged activation of the G2/M checkpoint in FANCA−/− cells grown in low-dose 
MMC for 9 days. (B) No difference in mitotic cell fraction between MMC-treated FANCA−/
− and FANCA+ cells indicates that the increased FANCA−/− G2/M fraction shown in (A) 
reflects G2 arrest prior to mitotic entry. (C, D) DNA replication arrest in FANCA−/− cells 
exposed to 1 nM MMC is rescued by FANCA gene correction. S-phase cells were labeled 
red by EdU incorporation. (E, F, G) Increased multinucleation due to DNA breakage, but 
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not chromosome missegregation, in FANCA−/− cells grown in low-dose MMC. (H, I) Flow 
cytometry shows decreased fraction of mitotic cells in FANCA−/− cells exposed to sublethal 
dose of taxol. (J, K) Treatment with taxol increases chromosome segregation errors and 
chromosome breakage in FANCA−/− cells. (L) Compound interphase and mitotic origins of 
genomic instability in FA-deficient cells (see text for discussion). Exponential accumulation 
of DNA damage may result in activation of cell cycle arrest/apoptosis (bone marrow failure) 
or malignant transformation (leukemia and solid tumors). All flow cytometry data represent 
pooled 3 replicates for each cell line and condition compared with two-tailed t-test. EdU 
incorporation counts were compared via two-way ANOVA with Sidak’s multiple 
comparisons test.
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